Current Report Filing (8-k)
December 23 2020 - 3:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 18, 2020
Twist Bioscience Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38720
|
|
46-205888
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I. R. S. Employer
Identification No.)
|
681 Gateway Boulevard
South San Francisco, CA 94080
(Address of principal executive offices, including ZIP code)
(800) 719-0671
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
TWST
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On December 18, 2020, Twist Bioscience Corporation (the Company) entered into a lease agreement (the ParkWorks Industry Center
Lease) with PWII Owner, LLC (the Landlord), with a commencement date of the later of (i) August 16, 2021 and (ii) the date the Landlord substantially completes installation of the tenant improvements (the
Commencement Date). The ParkWorks Industry Lease premises include approximately 110,995 square feet, located at 26600 S.W. Parkway Avenue, Wilsonville, Oregon (the Premises). The Company expects to use the
Premises primarily as a second manufacturing facility, although other permitted uses include office, life science laboratory, research and development, distribution and any other related uses. The ParkWorks Industry Center Lease has a 12-year term from the Commencement Date, and the Company has an option to extend the term of the ParkWorks Industry Center Lease by up to two additional five-year terms. The initial annual rent under the lease is
approximately $2.1 million (after partial rent abatement for the first year). The aggregate estimated rent payments due over the initial term of the ParkWorks Industry Center Lease is approximately $27.8 million. The Company is obligated
to pay 29.065% of the operating expenses and utilities applicable to the Premises. The Landlord will contribute an aggregate of approximately $13.3 million toward the cost of the tenant improvements. The Company will maintain a letter of credit
for the benefit of the Landlord in an amount of approximately $1.0 million.
The ParkWorks Industry Center Lease is filed as Exhibit 10.1 to this
report and the foregoing description of the terms of the ParkWorks Industry Center Lease is qualified in its entirety by reference to such exhibit.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
*
|
Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
Date: December 22, 2020
|
|
Twist Bioscience Corporation
|
|
|
|
|
/s/ Emily Leproust
|
|
|
Emily Leproust
|
|
|
Chief Executive Officer
|
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024